Take our quick assessment. Or, if you are a concerned observer, answer from your observations of their behavior. If you or the observed person have more than 1 of the listed symptoms above, a cognitive evaluation is in order.
Signs and symptoms of AD are not normal signs of aging. If you or someone you love is experiencing any of these symptoms, it is important to make an appointment as possible because AD worsens over time.
AD is a progressive disease and although there is no cure, the Bredesen’s protocol has been able to slow and reverse cognitive decline. Remember, the earlier AD is caught, the easier it is to successfully treat the condition.
Once a person has noticeable symptoms, they are in the later stages of cognitive decline. AD has an initial “silent phase,” where brain degeneration is occurring but these changes are not detectable using objective tests. Patients may, however, notice slight memory and cognitive changes. See the image below.
Understanding AD and dementia and separating them from “general aging”
AD is a form of dementia as illustrated by the graphic below:
For understanding and to separate Alzheimer’s from “normal aging” it is helpful to define AD. Alzheimer’s disease (AD) is an irreversible (?), progressive brain disorder that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks. It is characterized by the development of amyloid plaques and neurofibrillary, or tau, tangles; the loss of connections between nerve cells (neurons) in the brain; and the death of these nerve cells. It is the most common cause of dementia in older adults. While dementia is more common as people grow older, it is not a normal part of aging. There are two types of Alzheimer’s—early-onset (very rare) and late-onset. Both types have a genetic component.
- Early-onset AZ is caused by any one of a number of different single-gene mutations on chromosomes 21, 14, and 1. Each of these mutations causes abnormal proteins to be formed. Mutations on chromosome 21 cause the formation of abnormal amyloid precursor protein (APP). A mutation on chromosome 14 causes abnormal presenilin 1 to be made, and a mutation on chromosome 1 leads to abnormal presenilin 2.
Each of these mutations plays a role in the breakdown of APP, a protein whose precise function is not yet fully understood. This breakdown is part of a process that generates harmful forms of amyloid plaques, a hallmark of the disease.
- Most people with Alzheimer’s have the late-onset form of the disease, in which symptoms become apparent in the mid-60s and later. The causes of late-onset Alzheimer’s are not yet completely understood, but they likely include a combination of genetic, environmental, and lifestyle factors that affect a person’s risk for developing the disease.
Researchers have not found a specific gene that directly causes the late-onset form of the disease. However, one genetic risk factor—having one form of the apolipoprotein E (APOE) gene on chromosome 19—does increase a person’s risk. APOE comes in several different forms, or alleles:
- APOE ε2 is relatively rare and may provide some protection against the disease. If Alzheimer’s disease occurs in a person with this allele, it usually develops later in life than it would in someone with the APOE ε4 gene.
- APOE ε3, the most common allele, is believed to play a neutral role in the disease—neither decreasing nor increasing risk.
- APOE ε4 increases risk for Alzheimer’s disease and is also associated with an earlier age of disease onset. A person has zero, one, or two APOE ε4 alleles. Having more APOE ε4 alleles increases the risk of developing Alzheimer’s.
- APOE ε4 is called a risk-factor gene because it increases a person’s risk of developing the disease. However, inheriting an APOE ε4 allele does not mean that a person will definitely develop Alzheimer’s. Some people with an APOE ε4 allele never get the disease, and others who develop Alzheimer’s do not have any APOE ε4 alleles.
Understanding APOE and its role in development of AD
Apolipoprotein E (apoE) has multiple roles, including lipid transport in the blood and the brain. The APOE4 variant increases the risk for late-onset Alzheimer’s disease and may contribute to the pathology of the disease through influence on β-amyloid, inflammation, or other processes.
The risk for development of late-onset AD is increased approximately two- to threefold for individuals with one copy of the APOE4 variant and by approximately 10- to 15-fold for individuals with two copies of the variant (E4/E4 genotype). The APOE2 variant has some protective effect against development of late-onset AD. The lifetime risk for late-onset Alzheimer’s disease is approximately 10% to 12% in the general population, though it is higher in women than men and doubles when there is a first-degree relative with this disorder. The lifetime risk is approximately 9% for individuals negative for APOE4, and for individuals with E4/E4 may be as high as 25% for males and 45% for females. Among patients with late-onset AD, the presence of APOE4 may lead to earlier development of symptoms.
What can a person do to minimize their risk for developing AZ?
Given that science has not yet established a specific causal factor, it is believed that the development of the disease is based on a combination of genetics (APOE), lifestyle factors, history of head trauma (ex. Athletes like football players), mitochondrial damage and toxin exposure including biotoxins (Mold exposure). From our functional medicine underpinning, we know that mitochondrial damage can be initiated by free radical damage and that this can be mitigated through effective detoxification, proper nutritional supplementation, ensuring gut health, healthy eating and other lifestyle factors. From our knowledge about the damage inflicted by CIRS (Chronic Inflammatory Response Syndrome from mold exposure) it is easy to conceptualize how CIRS is related to cognitive decline as may CIRS patients experience reversible cognitive decline if CIRS is left untreated.
After much research, Dr. Lawson determined that the Bredesen protocol provides the best evidenced-based approach to diagnosing and treating cognitive decline from AD and related illnesses. The world renowned Dr. Dale Bredesen has created the ReCODE protocol that involves multiple strategies to address specific health issues that contribute to Alzheimer’s Disease (AD). The results of each strategy are measured by using blood tests, cognitive evaluations, and other markers of overall health improvements. Dr. Lawson is now Bredesen Certified as she has completed the study and certification requirements to be able to offer patients the full ReCODE protocol to help them recover from these debilitating illnesses.
At the forefront of this functional medicine approach to AD is Dr. Dale Bredesen and his team from the Buck Institute for Research on Aging. Through careful examination of the pathogenesis of Alzheimer’s, Dr. Bredesen and his team have found promising results. They have developed a multiple modality approach to achieving what they call metabolic enhancement for neurodegeneration (MEND), now referred to as Reversal of Cognitive Decline or ReCODE.
Through the approach Dr. Bredesen has developed, patients have been able to dramatically improve cognitive function, achieve reversal of symptoms, and in some cases, return to work. The ReCODE program includes lifestyle interventions, therapeutic diets, and targeted nutrients. We are excited to add this promising modality for the benefit of patients of Proactive Wellness Centers.
In short, our Brain Health Optimization (BHO) Evaluation and Treatment program includes the following elements:
Part 1: 2 hour in-office consultation with your Bredesen-Protocol doctor to review core test results in our Tyson’s office
Part 2: Physical Examination (usually on same day as Part 1)
Part 3: Baseline Cognitive Assessment (typically on same day as Part 1)
Part 4: 1.5 hour additional consultation with your Bredesen-Protocol doctor (Day 2 or later depending on availability of test results) at our Tyson’s office. This appointment can be in office or it can be a tele-video visit to cover the remaining tests that were not covered in the initial visit and review the core elements of a personalized treatment plan. In this visit, we will present the results of our evaluation in a personalized “cognoscopy”. We are sure that it will be enlightening.
Below is a detailed listing of the tests that are potentially included in the Comprehensive Brain Health Assessment.
- Comprehensive Initial Brain Health Assessment ($3475.00) Includes the following.
- Baseline labs and physical examination. A very complete set of baseline labs that will evaluate the entire spectrum of health and a baseline physical examination closely following the Bredesen protocol. This goes well beyond standard labs to include magnesium, zine and selenium levels, B6, B12 and folate levels, Omega 3 and omega 6 fatty acid levels, pre-diabetes evaluation, hormone levels, thyroid levels as well as specific immune markers like TH1, TH2, IL6 and TNF.
- A baseline Cognitive Assessment. This is to establish a baseline and evaluate you against an age-specific norm to determine the state of your cognitive function today. We are using the CNS Vital Signs cognitive assessment, one of the most highly regarded assessments in the industry.
- Apolipoprotein E (APOE) genetic test. We are aware that most patients have insurance but the problem is that most insurance companies are not covering genetic tests. And to help avoid patients getting an unexpectedly large bill, we are including this test in our program fee.
- Biotoxin illness Assessment. As there is emerging data to show that the presence of biotoxin illnesses greatly enhances a patient’s risk for developing AZ, this has to be a part of our brain health assessment. If indicated by a screening questionnaire, the panel leverages the most critical markers from the published literature for determining if a patient’s health is being impacted by CIRS including TGB-Beta 1, MSH, MMP9, HLA DRB1, 3,5, HLA DQB1, ADH/OS and several others.
- Comprehensive infection Assessment. If indicated by a screening questionnaire, the area of assessment and possible testing looks for borrelia, most Lyme coinfections including babesia, bartonella, ehrlichia, Anaplasma phagocytophilum, Chlamydophila pneumoniae and Rocky Mountain Spotted PCR Fever
- Chemical and heavy metals Immune Reactivity Screen. This area of testing looks for chronic and acute reactivity and antibodies across multiple chemicals and metals including aflatoxins, formaldehyde, bisphenol A, tetrachloroethylene, parabens, mercury, nickel, cobalt, cadmium, lead, arsenic
- Urine mycotoxin testing. Looks for presence of key mycotoxins in the urine. Mycotoxins are typically produced by mold exposure but there are other producers of mycotoxins as well.
- Microbiome testing. The gut microbiome resides in your large intestine and is host to more than 1000 species of bacteria that perform certain important functions from shaping the immune system to influencing metabolism of nutrients to fortifying the intestinal mucosal barrier. Microbiome testing helps to identify imbalances in the gut microbiome that may be causing gastrointestinal symptoms, skin conditions, autoimmune disorders, immune system imbalances, and multiple inflammatory disorders
- Blood brain barrier testing. This test is used to evaluate breaches of the Blood-Brain Barrier by stress, trauma or environmental triggers
- Inflammation/Immune/Auto-Immune Specialty Genetic Panel. This panel includes 30 gene variants that can affect one’s ability to control/ “turn off” inflammation. Chronic inflammation and oxidative stress can cause premature aging and most chronic diseases, including cancer and is a significant contributor to AD. Understanding a person’s genetic is valuable in both prevention and treatment.
- MRI with Neuroquant (NQ). Listed here for completeness. Not included in the price as this test is covered by most insurances. Used to assess the brain for structural issues and the NQ is used to determine if atrophy or hypertrophy has occurred in the various brain sectors. This is useful for assessing biotoxin illness as well as for broader use in AZ risk.
- Your own personalized “Cognoscopy”. The Cognoscopy is a summary report that brings together our findings from all of the testing mentioned above and summarizes your risks as it relates to each of the six Alzheimer’s types, and a summary clinical plan to optimize health and reverse mild cognitive decline if it has begun. Note that to get the actual prescriptions and clinical plan fine details, you must enroll in the Brain Health Optimization Program outlined below.
- Brain Health Optimization Program (BHOP) ($2975 – $9975 for 12 months depending on patient case specifics and scope of our services). Note, price does not include any medications or supplements except as indicated below. Further, note that all patients who enroll in our Brain Health Optimization Program must commit to a one-year “REVERSE” subscription at $75 per month with Dr. Bredesen at https://apollo.ahnphealth.com/logins/new
- Specific and individually tailored lifestyle modification guidance. Through this program component, we will provide specific and tailored guidance to apply all of the lifestyle modifications that we are currently aware of that help to mitigate risk for developing AD. Naturally, this area will continue to emerge so it will be very dynamic as more emerging credible data is published.
- Bioidentical Hormone Replacement as indicated by test results
- Treatment for biotoxin and other chronic illnesses as indicated by test results
- Development and adjustment as needed of a comprehensive clinical plan for the patient that is driven by the ReCode recommendations
- Specific recommended nutritional supplements to enhance brain health. Currently there are two specific supplements that we are using that are supported by solid science and the patient will be supplied with these for the duration of the program. The two supplements are listed below and the price includes a supply of these nutrients for the duration of the program:
- Microdose Lithium. Lithium has been shown to inhibit the destructive GSK-3 enzyme. GSK-3 is implicated in the chemical changes that destroy brain cells and impair memory. In very high doses, lithium is used for other purposes but the micro-dose lithium has been validated for its GSK-3 inhibiting impact and therefore favorable impact on brain health and avoiding AZ.
- Microdose Proline Rich Polypeptides (PRPS) a/k/a Colostrinin, a component of colostrum. Research shows it improves the mental functioning of Alzheimer’s patients. Researchers at the University Medical School in Wroclaw, Poland, conducted a double-blind, placebo-controlled study showing that oral administration of colostrinin, a proline-rich polypeptide (PRP) complex isolated from colostrum, improves the outcome of AD patients with mild to moderate dementia’ Additionally, colostrinin was found to be a remarkably safe natural supplement.
- Followup Cognitive Assessments 6 months after program commencement and 11 months. We will compare the results of this assessment with the baseline to determine improvement and/or degradation in cognitive function.
Already have labs and your Recode report and just need a physician to review your Recode report and advise of recommended next steps? For this, our Bredesen Recode Report Consultation is the place to start. The fee for this is $975.00 and includes a 2 hour physician review and consultation preceded by a cognitive evaluation and physical examination.
We are truly excited to bring this program forth to our patient population. Dr. Lawson is passionate about this area of our health and she is committed to being on the leading-edge or the emerging treatment protocols. Ready to get started? Use one of the options below.
- Click here to contact us on our quick contact form and someone will get back with you shortly.
- If between the hours of 9:00 AM – 5:00 PM Monday through Friday, feel free to call us now on (703) 822-5003 and our Clinical Intake Coordinator will answer any question you have and get you started.
- If you know this is the program for you, then Click here to begin the online enrollment process
Not ready to start for sure, but just want to get a 30 minute age-normalized cognitive assessment, MoCA evaluation with 30 minute clinical review for $500, then Click here to learn more about our quick but comprehensive neurocognitive assessment.
Helpful Resources for Alzheimer’s disease and the Bredesen Protocol
Here is the proof that the Bredesen Protocol really works. Over 100 patients, multiple practitioners, multiple geographies, results sustained over time. Click here to read the details:
Check out this report that concludes why existing drugs and drugs that once showed promise in early clinical trials have failed. Bottom line, Dr. Bredesen and the ReCode protocol has the answers. Traditional therapies are stuck looking for the “magic bullet”. Click here to read more…